Brown Forman (BF.A) to pay $0.20 on Jan 2, 2018; Ocera Therapeutics, Inc. (OCRX) Had 2 Analysts Last Week

December 5, 2017 - By wolcottdaily

Brown Forman Corporation (NYSE:BF.A) is expected to pay $0.20 on Jan 2, 2018. $0.79 is the ADY. (NYSE:BF.A) shareholders before Dec 6, 2017 will receive the $0.20 dividend. Brown Forman Corporation’s current price of $62.57 translates into 0.32% yield. Brown Forman Corporation’s dividend has Dec 7, 2017 as record date. Nov 16, 2017 is the announcement. The stock increased 2.46% or $1.5 during the last trading session, reaching $62.57. About 27,354 shares traded or 25.04% up from the average. Brown-Forman Corporation (NYSE:BF.A) has risen 3.71% since December 5, 2016 and is uptrending. It has underperformed by 12.99% the S&P500.

Among 5 analysts covering Ocera Therapeutics (NASDAQ:OCRX), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Ocera Therapeutics has $11 highest and $1.0 lowest target. $7’s average target is 300.00% above currents $1.75 stock price. Ocera Therapeutics had 10 analyst reports since November 6, 2015 according to SRatingsIntel. H.C. Wainwright maintained Ocera Therapeutics, Inc. (NASDAQ:OCRX) rating on Monday, June 5. H.C. Wainwright has “Buy” rating and $400 target. Brean Capital initiated it with “Buy” rating and $10 target in Tuesday, February 23 report. The company was initiated on Wednesday, December 28 by H.C. Wainwright. As per Friday, November 4, the company rating was initiated by Aegis Capital. The company was downgraded on Tuesday, January 31 by JMP Securities. The company was maintained on Monday, June 5 by Aegis Capital. The stock of Ocera Therapeutics, Inc. (NASDAQ:OCRX) earned “Hold” rating by Stifel Nicolaus on Wednesday, August 2. The stock has “Neutral” rating by H.C. Wainwright on Friday, November 3. On Friday, October 27 the stock rating was maintained by Stifel Nicolaus with “Hold”. See Ocera Therapeutics, Inc. (NASDAQ:OCRX) latest ratings:

03/11/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $10 Downgrade
27/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $1.0 Maintain
02/08/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $1.0000 Maintain

It closed at $1.75 lastly. It is down 55.77% since December 5, 2016 and is downtrending. It has underperformed by 72.47% the S&P500.

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $46.40 million. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury or failure, and in the areas of unmet medical need. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.